Role of soluble receptor ST2 measurment in diagnosis and prognostic stratification in patients with heart failure

Česká verzia

Authors: Filip Málek; Dagmar Vondráková; Petr Neužil
Authors place of work: Kardiologické oddělení Kardiocentra Nemocnice Na Homolce, Praha, přednosta MUDr. Ivo Skalský, Ph. D., MBA
Published in the journal: Vnitř Lék 2015; 61(12): 1039-1041
Category: Reviews

Summary

ST2 is a member of the interleukin 1 (IL1) receptor family and consists of a trans-membrane ligand (STL2) and a soluble form (sST2). sST2 is released from cardiomyocytes and fibroblasts after mechanical strain and has been identified as a novel biomarker of cardiac stress, fibrosis and remodelling. Many studies showed that sST2 brings important prognostic information in patients with heart failure. Elevated sST2 concentrations predicted risk of hospitalization and mortality independently on natriuretic peptides levels and on other clinical variables. Some studies showed diagnostic role of sST2 u patients with heart failure and normal ejection fraction.

Key words:
diagnosis – heart failure – prognostic stratification – sST2

Zdroje

1. Braunwald E. Biomarkers in heart failure. New Engl J Med 2008; 358(20): 2148–2159.

2. Bejšovec R, Jokl I. Natriuretický peptid typu B (BNP) – použitelnost v diferenciální diagnostice dušnosti. Vnitř Lék 2005; 51(6): 658–663.

3. van Veldhuisen DJ, Linssen GC, Jaarsma T et al. B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. J Am Coll Cardiol 2013; 61(14): 1498–1506.

4. Sanada S, Hakuno D, Higgins LJ et al. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 2007; 117(6): 1538–1549.

5. Weinberg EO, Shimpo M, De Keulenaer GW et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 2002; 106(23): 2961–2966.

6. Rehman SU, Mueller T, Januzzi JL jr.Characteristics of the Novel Interleukin Family Biomarker ST2 in Patients With Acute Heart Failure. J Am Coll Cardiol 2008; 52(18):1458–1465.

7. Manzano-Fernández S, Mueller T, Pascual-Figal D et al. Usefulness of soluble concentrations of interleukin family member st2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. Am J Cardiol 2011; 107(2): 259–267.

8. Ky B, French B, Levy WC et al. Multiple biomarkers for risk prediction in chronic heart failure. Circ Heart Fail 2012; 5(2): 183–190.

9. Chen LQ, de Lemos JA, Das SR et al. Soluble ST2 is associated with all-cause and cardiovascular mortality in a population-based cohort: The Dallas Heart Study. Clin Chem 2013; 59(3): 536–546.

10. Januzzi JL Jr, Peacock WF, Maisel AS et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol 2007; 50(7): 607–613.

11. Dieplinger B, Gegenhuber A, Kaar G Prognostic value of established and novel biomarkers in patients with shortness of breath attending an emergency department. Clin Biochem 2010; 43(9): 714–719.

12. Shah RV, Chen-Tournoux AA, Picard MH et al. Serum levels of the interleukin-1 receptor family member ST2, cardiac structure and function, and long-term mortality in patients with acute dyspnea. Circ Heart Fail 2009; 2(4): 311–319.

13. Mangan NE, Dasvarma A, McKenzie AN et al. T1/ST2 expression on Th2 cells negatively regulates allergic pulmonary inflammation. Eur J Immunol 2007; 37(5): 1302–1312.

14. Oshikawa K, Kuroiwa K, Tago K et al. Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. Am J Respir Crit Care Med 2001; 164(2): 277–281.

15. Tajima S, Oshikawa K, Tominaga S et al. The increase in serum soluble ST2 protein upon acute exacerbation of idiopathic pulmonary fibrosis. Chest 2003; 124(4): 1206–1214.

16. Martinez-Rumayor A, Camargo CA, Green SM et al. Soluble ST2 Plasma Concentrations Predict 1-Year Mortality in Acutely Dyspneic Emergency Department Patients With Pulmonary Disease. Am J Clin Pathol 2008; 130(4): 578–584.

17. Pařenica J, Malaska J, Jarkovský J et al. Soluble ST2 levels in patients with cardiogenic and septic shock are not predictors of mortality. Exp Clin Cardiol 2012; 17(4): 205–209.

18. Boisot S, Beede J, Isakson S et al. Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure. J Card Fail 2008; 14(9): 732–738.

19. Diez J. Serum soluble ST2 as a biochemical marker of acute heart failure. J Am Coll Cardiol 2008; 52(18): 1466–1467.

20. Mueller T, Dieplinger B, Gegenhuber A et al. Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Clin Chem 2008; 54(4): 752–756.

21. Weinberg EO, Shimpo M, Hurwitz S et al. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 2003; 107(5): 721–726.

22. Bartunek J, Delrue L, van Durme F et al. Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load. J Am Coll Cardiol 2008; 52(25): 2166–2174.

23. Wang YC, Yu CC, Chiu FC et al. Soluble ST2 as a biomarker for detecting stable heart failure with a normal ejection fraction in hypertensive patients. J Card Fail 2013; 19(3): 163–168.

24. Santhanakrishnan R, Chong JP, Ng TP et al. Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction. Eur J Heart Fail 2012; 14(12): 1338–1347.

25. Cheng JM, Akkerhuis KM, Battes LC et al. Biomarkers of heart failure with normal ejection fraction: a systematic review. Eur J Heart Fail 2013; 15(12): 1350–1362.

26. Bayes-Genis A, de Antonio M, Galán A et al. Combined use of high-sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure. Eur J Heart Fail 2012; 14(1): 32–38.

27. Zethelius B, Berglund L, Sundström J et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl JMed 2008; 358(20): 2107–2116.

28. Bayes-Genis A, Zamora E, de Antonio M et al. Soluble ST2 serum concentration and renal function in heart failure. J Card Fail 2013; 19(11): 768–775.